Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014;32:3365–3373.

• PubMed
Fakhry C, Zhang Q, Nguyen-Tan PF, Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014;32:3365–3373.)| false
• Search Google Scholar
• Export Citation

Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394:1915–1928.

• PubMed
Burtness B, Harrington KJ, Greil R, Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394:1915–1928.)| false
• Search Google Scholar
• Export Citation

Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–1127.

• PubMed
Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–1127.)| false
• Search Google Scholar
• Export Citation

Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol 2023;41:790–802.

• PubMed
Harrington KJ, Burtness B, Greil R, Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol 2023;41:790–802.)| false
• Search Google Scholar
• Export Citation

Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–1867.

• PubMed
Ferris RL, Blumenschein G Jr, Fayette J, Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–1867.)| false
• Search Google Scholar
• Export Citation

Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393:156–167.

• PubMed
Cohen EEW, Soulières D, Le Tourneau C, Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393:156–167.)| false
• Search Google Scholar
• Export Citation

Mai HQ, Chen QY, Chen D, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA 2023;330:1961–1970.

• PubMed
Mai HQ, Chen QY, Chen D, Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA 2023;330:1961–1970.)| false
• Search Google Scholar
• Export Citation

Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol 2021;22:883–892.

• PubMed
Sacco AG, Chen R, Worden FP, Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol 2021;22:883–892.)| false
• Search Google Scholar
• Export Citation

Chung CH, Li J, Steuer CE, et al. Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma. Clin Cancer Res 2022;28:2329–2338.

• PubMed
Chung CH, Li J, Steuer CE, Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma. Clin Cancer Res 2022;28:2329–2338.)| false
• Search Google Scholar
• Export Citation

Hanna GJ, Kaczmar JM, Zandberg DP, et al. Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. J Clin Oncol 2023;41(Suppl):Abstract 6005.

• PubMed
Hanna GJ, Kaczmar JM, Zandberg DP, Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. J Clin Oncol 2023;41(Suppl):Abstract 6005.)| false
• Search Google Scholar
• Export Citation

Dzienis MR, Cundom JE, Fuentes CS, et al. Pembrolizumab plus carboplatin plus paclitaxel as first-line therapy in recurrent/metastatic head and neck squamous cell carcinoma: phase VI KEYNOTE-B10 study. Ann Oncol 2022;33(Suppl 7):Abstract 651O.

• PubMed
Dzienis MR, Cundom JE, Fuentes CS, Pembrolizumab plus carboplatin plus paclitaxel as first-line therapy in recurrent/metastatic head and neck squamous cell carcinoma: phase VI KEYNOTE-B10 study. Ann Oncol 2022;33(Suppl 7):Abstract 651O.)| false
• Search Google Scholar
• Export Citation

Fayette J, Cropet C, Gautier J, et al. Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible for cisplatin-based therapies. J Clin Oncol 2023;41(Suppl):Abstract 6003.

• PubMed
Fayette J, Cropet C, Gautier J, Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible for cisplatin-based therapies. J Clin Oncol 2023;41(Suppl):Abstract 6003.)| false
• Search Google Scholar
• Export Citation

Saba NF, Steuer CE, Ekpenyong A, et al. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat Med 2023;29:880–887.

• PubMed
Saba NF, Steuer CE, Ekpenyong A, Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat Med 2023;29:880–887.)| false
• Search Google Scholar
• Export Citation

Chung C, Colevas D, Adkins D, et al. A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. Presented at Society for Immunotherapy of Cancer’s 37th Annual Meeting; November 10–14, 2022; Boston, MA. Abstract 681.

• PubMed
Chung C, Colevas D, Adkins D, A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. Presented at Society for Immunotherapy of Cancer’s 37th Annual Meeting; November 10–14, 2022; Boston, MA. Abstract 681.)| false
• Search Google Scholar
• Export Citation

Price KAR, Kaczmar JM, Worden FP, et al. Safety and efficacy of immune checkpoint inhibitor naive cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma. J Clin Oncol 2023;41(Suppl):Abstract 6012.

• PubMed
Price KAR, Kaczmar JM, Worden FP, Safety and efficacy of immune checkpoint inhibitor naive cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma. J Clin Oncol 2023;41(Suppl):Abstract 6012.)| false
• Search Google Scholar
• Export Citation

Swiecicki P, Yilmaz E, Rosenberg AJ, et al. Enfortumab vedotin in the previously treated advanced head and neck cancer cohort of EV-202. J Clin Oncol 2023;41(Suppl):Abstract 6017.

• PubMed
Swiecicki P, Yilmaz E, Rosenberg AJ, Enfortumab vedotin in the previously treated advanced head and neck cancer cohort of EV-202. J Clin Oncol 2023;41(Suppl):Abstract 6017.)| false
• Search Google Scholar
• Export Citation

Yom SS, Torres-Saavedra PA, Kuperwasser C, et al. Association of plasma tumor tissue modified viral HPV DNA with tumor burden, treatment type, and outcome: a translational analysis from NRG-HN002. J Clin Oncol 2022;40(Suppl):Abstract 6006.

• PubMed
Yom SS, Torres-Saavedra PA, Kuperwasser C, Association of plasma tumor tissue modified viral HPV DNA with tumor burden, treatment type, and outcome: a translational analysis from NRG-HN002. J Clin Oncol 2022;40(Suppl):Abstract 6006.)| false
• Search Google Scholar
• Export Citation

Ho AL, Brana I, Haddad R, et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol 2021;39:1856–1864.

• PubMed
Ho AL, Brana I, Haddad R, Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol 2021;39:1856–1864.)| false
• Search Google Scholar
• Export Citation